GGrantIndex
← Leaderboards

Jesus Rivera-Nieves

Va San Diego Healthcare System

Google Scholar ↗PubMed ↗ORCID ↗
$10,753,559
Attributed
$12,910,085
Total exposure
12
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,910,085 · 9
VA$0 · 3

By mechanism

R01$10,745,001 · 4
R21$825,365 · 2
K08$687,920 · 1
K26$335,838 · 1
R03$315,961 · 1
I01$0 · 3

Top collaborators

Others in their field

Top investigators on “Cells”

Research focus

CellsIntestinesResponsePharmaceutical PreparationsT-LymphocyteIleitisChronicTnf GeneMouse ModelLymphocyteInflammatory Bowel DiseasesLeadAffectIntegrinsPathogenesisCrohn&AposPathway InteractionsBaseHomingLigandsMucosal Addressin Cell Adhesion Molecule-1InflammatoryS DiseaseCell Physiology

Grant awards (46)

HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues$774,121
R01 · FY2025 · DK
Integrin αEβ7-dependent IgA transcytosis during homeostasis and IBD$643,920
R01 · FY2025 · DK · contact PI
Enhancing Mentoring of Diverse Early Career Researchers$111,946
K26 · FY2025 · DK · contact PI
Control by Beta 7 integrins of the bacterial triggers of IBD$0
I01 · FY2025 · VA · contact PI
HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues$747,184
R01 · FY2024 · DK
Enhancing Mentoring of Diverse Early Career Researchers$111,946
K26 · FY2024 · DK · contact PI
Control by Beta 7 integrins of the bacterial triggers of IBD$0
I01 · FY2024 · VA · contact PI
HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues$782,136
R01 · FY2023 · DK
Integrin αEβ7-dependent IgA transcytosis during homeostasis and IBD$643,676
R01 · FY2023 · DK · contact PI
Enhancing Mentoring of Diverse Early Career Researchers$111,946
K26 · FY2023 · DK · contact PI
Control by Beta 7 integrins of the bacterial triggers of IBD$0
I01 · FY2023 · VA · contact PI
HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues$786,123
R01 · FY2022 · DK
Integrin αEβ7-dependent IgA transcytosis during homeostasis and IBD$642,908
R01 · FY2022 · DK · contact PI
Dendritic Cell Regulation by Sphingosine-1-phosphate in Inflammatory Bowel Disease$0
I01 · FY2022 · VA · contact PI
HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues$789,998
R01 · FY2021 · DK
Immunoprofiling for identifying biomarkers in celiac disease$197,240
R21 · FY2021 · AI · contact PI
Dendritic Cell Regulation by Sphingosine-1-phosphate in Inflammatory Bowel Disease$0
I01 · FY2021 · VA · contact PI
Novel Traffic-targeted Therapies for IBD$659,323
R01 · FY2020 · DK · contact PI
Immunoprofiling for identifying biomarkers in celiac disease$236,250
R21 · FY2020 · AI
High Dimensional Mass Cytometry Analysis of the Effects of Vedolizumab in Intestinal Cellular Subsets and its Correlation with Clinical Parameters$178,125
R21 · FY2020 · DK · contact PI
Dendritic Cell Regulation by Sphingosine-1-phosphate in Inflammatory Bowel Disease$0
I01 · FY2020 · VA · contact PI
Novel Traffic-targeted Therapies for IBD$659,323
R01 · FY2019 · DK · contact PI
High Dimensional Mass Cytometry Analysis of the Effects of Vedolizumab in Intestinal Cellular Subsets and its Correlation with Clinical Parameters$213,750
R21 · FY2019 · DK · contact PI
Dendritic Cell Regulation by Sphingosine-1-phosphate in Inflammatory Bowel Disease$0
I01 · FY2019 · VA · contact PI
Novel Traffic-targeted Therapies for IBD$645,373
R01 · FY2018 · DK · contact PI
Novel Traffic-targeted Therapies for IBD$645,373
R01 · FY2017 · DK · contact PI
Novel Traffic-targeted Therapies for IBD$659,123
R01 · FY2016 · DK · contact PI
Dendritic Cell Manipulation: A Novel Therapeutic for Inflammatory Bowel Disease$0
I01 · FY2015 · VA · contact PI
Dendritic Cell Manipulation: A Novel Therapeutic for Inflammatory Bowel Disease$0
I01 · FY2014 · VA · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$290,875
R01 · FY2013 · DK · contact PI
Dendritic Cell Manipulation: A Novel Therapeutic for Inflammatory Bowel Disease$0
I01 · FY2013 · VA · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$304,489
R01 · FY2012 · DK · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$37,703
R01 · FY2012 · DK · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$301,425
R01 · FY2011 · DK · contact PI
Dendritic Cell Manipulation: A Novel Therapeutic for Inflammatory Bowel Disease$0
I01 · FY2011 · VA · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$363,528
R01 · FY2010 · DK · contact PI
Targeting L-Selectin in Chronic Murine Ileitis$368,400
R01 · FY2009 · DK · contact PI
Lymphocyte Trafficking by Chemokines/Adhesion Molecules in Crohn's Disease$48,695
K08 · FY2009 · DK · contact PI
Role of L-selectin and its Ligands in Chronic Murine Ileitis$136,266
R03 · FY2008 · DK · contact PI
Lymphocyte Trafficking by Chemokines/Adhesion Molecules in Crohn's Disease$127,845
K08 · FY2008 · DK · contact PI
Role of L-selectin and its Ligands in Chronic Murine Ileitis$139,047
R03 · FY2007 · DK · contact PI
Lymphocyte Trafficking by Chemokines/Adhesion Molecules in Crohn's Disease$127,845
K08 · FY2007 · DK · contact PI
Regulate/Lymphocyte Traffic/Chemokines/Adhesion/Crohn's$127,845
K08 · FY2006 · DK · contact PI
Role of L-selectin and its Ligands in Chronic Murine Ileitis$40,648
R03 · FY2006 · DK · contact PI
Regulate/Lymphocyte Traffic/Chemokines/Adhesion/Crohn's$127,845
K08 · FY2005 · DK
Lymphocyte Trafficking by Chemokines in Crohn's Disease$127,845
K08 · FY2004 · DK